DraftUnitedHealthcarePolicy CSNCT0415.02

Gastrointestinal Motility Disorders, Diagnosis and Treatment (for North Carolina Only)

Policy governs diagnostic testing and treatment options for gastrointestinal motility disorders (e.g., gastroparesis, constipation, anorectal disorders, fecal incontinence) for UnitedHealthcare members in North Carolina.

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Motility Disorders, Diagnosis and Treatment (for North Carolina Only)

Policy CodePolicy CSNCT0415.02

Change TypeState-specific versioncoding and coverage clarifications

Effective DateOct 1, 2025

Next Review Date

Key ActionPrior authorize GES (Enterra) with documentation of medically refractory gastroparesis after standard therapy, symptom severity, and etiology.

SourceLink

POLICY UPDATE CHANGES

Coverage Rationale: Esophageal Mucosal Integrity Testing by electrical impedance (e.g., MiVu Mucosal Integrity Testing System) for diagnosis of GERD, EoE, and nonacid reflux disease or for monitoring treatment response are unproven and not medically necessary due to insufficient evidence.

Language indicating rectal manometry, rectal sensation, tone, and compliance test, conventional defecography, and anorectal manometry are proven and medically necessary for evaluation of colorectal function was removed.

Language indicating colonic manometry is unproven and not medically necessary was removed.

Language indicating ingestible vibrating capsule devices (e.g., Vibrant System) for constipation are unproven and not medically necessary was removed.

Medical Records Documentation section updated to clarify that documentation may be required to assess clinical criteria but does not guarantee coverage, and that benefit coverage is determined by applicable federal, state, or contractual requirements.

Definition of 'Esophageal Mucosal Integrity Testing' was added to the policy.

Applicable CPT codes 43499 and 76498 were added; several CPT/HCPCS codes (74270, 76496, 91117, 91120, 91122, A9286, A9900, A9999, E1399) were removed.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

GESGES proven for refractory gastroparesis

3+Unproven / not medically necessary tests

12Applicable CPT/HCPCS codes referenced

>=2CPT codes added/removed

NCState-specific version

Coverage Criteria and Evidence Summary

Esophageal Mucosal Integrity Testing - Evidence and Utility

Esophageal Mucosal Integrity Testing — Evidence and Utility

The available published clinical studies on esophageal mucosal integrity (MI) testing by electrical impedance are limited in number and generally of low to very low quality. Systematic and evidence-review organizations (Hayes 2022, updated 2024; ECRI 2021) concluded that current evidence is insufficient to establish the safety and effectiveness of MI testing for diagnosis of GERD, eosinophilic esophagitis (EoE), or nonacid reflux disease, or for monitoring treatment response in GERD and EoE.

Hayes (2022, updated 2024) reviewed three very-poor-quality studies and one systematic review and stated the device may distinguish previously diagnosed EoE from GERD at least as well as EGD and potentially better than pH testing; however, Hayes emphasized the lack of data on participants without a definitive diagnosis and concluded there is insufficient evidence of clinical utility (impact on management or outcomes).

ECRI (2021) identified three relevant studies and concluded evidence was limited; larger clinical validity studies and clinical utility studies are needed to assess diagnostic accuracy and whether MI-guided care improves patient-relevant outcomes.

Patel et al. (2019): Prospective multicenter test-validation study (n=69) reported distinct MI patterns among GERD, EoE, and non-GERD groups and suggested MI testing detected changes in mucosal integrity during endoscopy; limitations included small sample size, lack of blinding, homogeneous population, and assumptions about group prevalence — findings require validation in independent populations and do not establish clinical utility.

Choksi et al. (2018): Retrospective analysis (n=91) reported MI patterns that differentiated EoE from GERD/non-GERD and a validation cohort that supported diagnostic separation; limitations included small sample sizes, limited sensing channels, manual repositioning variability, and homogeneous study populations. Clinical utility was not demonstrated.

Overall conclusion: Evidence to date demonstrates that MI testing can detect differences in esophageal impedance patterns across diagnostic groups, but studies are limited by small size, methodological concerns, and lack of prospective, multicenter clinical utility data showing improved patient outcomes or impact on management. Additional well-designed clinical validity and clinical utility studies with larger, diverse populations and independent validation are required before routine clinical use can be recommended.

Applicable Procedure and Device Codes

Covered / Applicable CPT and HCPCS codesmixed

0779T	Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report
0868T	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report
43499	Unlisted procedure, esophagus
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array
72195	Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s)

1–10 of 15

1/2

Codes mentioned in excerptmixed

Policy Number	CSNCT0415.02
Effective Date	October 1, 2025

Device product codes and regulatory identifiersmixed

MYE	FDA product code for instruments to perform cutaneous electrogastrography/electroenterography/body surface gastric mapping
FFX	Alternate FDA product code for related gastric mapping instruments
QIS	FDA product code for MiVu Mucosal Integrity Testing System (MiVu) — see 510(k) K230056
Enterra HDE	Enterra Therapy System (Medtronic) — marketed under Humanitarian Device Exemption (HDE), HDE ID 376493

Added CPT CodesCPT

43499	Unlisted procedure, esophagus (added)
76498	Unlisted magnetic resonance procedure (added)

Removed CPT/HCPCS Codesmixed

74270	(removed)
76496	(removed)
91117	(removed)
91120	(removed)
91122	(removed)
A9286	(removed)
A9900	(removed)
A9999	(removed)
E1399	(removed)

ARA change threshold (MRD) — single-study threshold detail

ARA change threshold (MRD)< 1.5 degrees

Prior Authorization, Documentation, and Operational Notes

Prior Authorization

Referenced procedure codes may require prior authorization

Procedure codes listed in the policy are provided for reference and may be subject to prior authorization per benefit plan and state requirements.

Referenced codes include: 0779T, 0868T, 43499, 43647, 43648, 43881, 43882, 64590, 64595, 72195, 72196, 72197, 76498, 91132, 91133.

Prior Authorization

Prior authorization recommended for GES (Enterra)

Prior authorization is recommended for GES (Enterra) with documentation demonstrating medically refractory gastroparesis after failure of standard therapies, symptom severity, and etiology (diabetic, idiopathic, postsurgical) to support selection.

Document trials of standard therapies and symptom severity scores (e.g., PAGI-SYM, TSS).
Indicate gastroparesis etiology (diabetic, idiopathic, postsurgical).

Clinical Background and Evidence Context

Gastroparesis is characterized by delayed gastric emptying and presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diabetes is a common etiology. Diagnosis requires objective evidence of delayed gastric emptying (gastric emptying scintigraphy remains the reference standard), and management pathways include medical, dietary, and procedural options for refractory cases.

Definitions and Terminology

Anorectal Disorders

DefinitionStructural or functional abnormalities of the anorectum or pelvic floor.

Source exampleCited reference: Patcharatrakul and Rao, 2018.

Clinical contextIncludes conditions evaluated with tests such as MR defecography, anorectal manometry, and balloon expulsion testing.

Constipation

DefinitionInfrequent or hard-to-pass bowel movements, hard stools, or sensation of incomplete evacuation; infrequent defined as fewer than three bowel movements per week.

ReferenceDefinition derived from Bharucha et al., 2013a as cited in the policy.

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Motility Disorders, Diagnosis and Treatment (for North Carolina Only)

Policy CodePolicy CSNCT0415.02

Change TypeState-specific versioncoding and coverage clarifications

Effective DateOct 1, 2025

Next Review Date

Key ActionPrior authorize GES (Enterra) with documentation of medically refractory gastroparesis after standard therapy, symptom severity, and etiology.

SourceLink

On This Page

Documentation Required

Document device regulatory status and institutional oversight

Document device regulatory status and any required institutional oversight; Enterra is marketed under an FDA Humanitarian Device Exemption (HDE) and use should follow FDA labeling and applicable IRB/institutional approvals.

For GES (Enterra), reference FDA HDE labeling and contraindications when submitting for authorization.
For other devices (EGG/BSGM, MiVu), note FDA device class and product codes as applicable.

Billing Rule

New CPT codes added that may impact prior authorization

CPT codes 43499 and 76498 were added to the Applicable Codes section; prior authorization requirements should follow the payer's rules for services requiring review.

Added: 43499, 76498.
Removed codes are listed in Policy History and may affect billing/authorization workflows.

Step Therapy

Require documentation of refractory therapy before GES

GES is intended for medically refractory gastroparesis after failure of other therapies; prior trials of standard therapies should be documented before considering GES.

Indicate that symptoms are drug-refractory and that standard therapies were attempted and failed.

Step Therapy

Conservative therapies must be tried and documented first

Prior noninvasive and medical therapies should be attempted and documented before advanced interventions (e.g., GES, MR defecography).

For gastroparesis, document dietary modification and appropriate medication trials.
For defecatory disorders, document trials of dietary/laxative therapy and anorectal testing (ARM, BET) when indicated.

Note

Follow society guidance — avoid routine EGG for refractory gastroparesis

Professional society guidance does not recommend routine use of electrogastrography (EGG) for refractory gastroparesis; use standard diagnostic pathways before ordering investigational EGG/BSGM.

AGA position statement and updated guidance do not support routine EGG use.
EGG/BSGM remain investigational pending stronger evidence of clinical utility.

Denial Risk

Codes listed do not imply coverage — verify contractual requirements

Inclusion of codes in the policy does not guarantee coverage; benefit coverage is determined by federal, state, or contractual requirements and applicable laws.

Medical records documentation may be required to determine if member meets clinical criteria.
Coverage decisions may differ based on the member's plan or jurisdiction.

Documentation Required

Medical records may be requested for review

Medical records documentation may be required to assess whether the member meets clinical criteria for coverage; submission of records does not guarantee approval.

Refer to the Medical Records Documentation Used for Reviews guidance when preparing prior authorization requests.

Documentation Required

Required clinical documentation when requesting GES

For GES (Enterra) requests, include symptom severity scores (e.g., PAGI-SYM, TSS), Clinical Patient Grading Assessment Scale (CPGAS) responses, prior standard therapy trials, and etiology (diabetic, idiopathic, postsurgical).

Provide baseline and follow-up symptom scores and objective data showing refractory symptoms.
Document prior interventions, response, and rationale for GES candidacy.

Documentation Required

Required clinical documentation for MR defecography

For MR defecography (MRD) requests, include prior anorectal manometry (ARM) and balloon expulsion test (BET) results when performed, the clinical indication (e.g., obstructed defecation), and whether evacuation-phase imaging was performed.

Document that ARM/BET were equivocal or insufficient if MRD is being requested as an adjunctive test.
State the clinical question MRD is intended to answer (e.g., enterocele, rectocele, pelvic floor anatomy).

Documentation Required

Pre-test preparation and work-up required for BSGM

Studies reporting BSGM typically require prior clinical work-up (e.g., upper endoscopy to exclude alternative pathology), withholding medications affecting motility for 48 hours, overnight fasting, and avoidance of caffeine, nicotine, opioids, and cannabis on test day; document these preparatory steps to support test validity.

Confirm upper endoscopy performed to exclude alternative causes when indicated.
Document medication withholding and fasting instructions were followed on test day.

Documentation Required

Medical records may be required — documentation does not ensure coverage

Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage; documentation does not guarantee coverage and determinations follow applicable federal, state, or contractual requirements.

Ensure submitted records clearly demonstrate how the member meets policy criteria.

Denial Risk

Coverage contingent on contract and medical record review

Inclusion of a code in the policy does not imply coverage; benefit coverage is determined by federal, state, or contractual requirements and medical records may be required to assess whether the member meets clinical criteria.

Verify member-specific plan and jurisdictional requirements before scheduling or billing.

Denial Risk

Evidence limitations may lead to denial or additional justification requests

Limited quality of evidence, small studies, and lack of comparison groups for some interventions (e.g., GES in non-diabetic or idiopathic patients) may prompt denial or requests for additional justification.

Be prepared to submit longitudinal outcomes or stronger rationale for off-label or less-supported indications.

Denial Risk

Denial risk when MRD is non-diagnostic or used alone

MRI defecography has variable technical success and may under-detect abnormalities compared with fluoroscopic defecography; inconclusive or non-diagnostic MRD studies could prompt repeat testing or denial if used as sole diagnostic evidence.

If MRD is requested, document why fluoroscopic defecography or other tests were insufficient or unavailable.

Denial Risk

Check Enterra contraindications before authorizing GES

Enterra HDE labeling lists contraindications (gastric obstruction/pseudo-obstruction, prior gastric resection, fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting); presence of these conditions would preclude appropriate use and could trigger denial.

Verify and document absence of listed contraindications when requesting GES.

Denial Risk

Denial risk for MiVu electrical impedance testing (MiVu)

Requests for esophageal mucosal integrity testing by electrical impedance (e.g., MiVu) for diagnosis of GERD, EoE, nonacid reflux disease, or for monitoring treatment response are considered unproven and not medically necessary and are subject to denial.

Do not rely on MiVu electrical impedance testing as a standalone diagnostic or monitoring tool for GERD/EoE without additional validated clinical evidence.

Constipation is a common indication for anorectal and colonic functional testing when conservative measures fail.

Electrogastrography (EGG)

DefinitionA non-invasive method to measure gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

Clinical utility statementPolicy notes EGG and related surface mapping techniques detect gastric myoelectrical abnormalities but current evidence does not demonstrate consistent clinical utility for diagnosis or improved patient outcomes.

ReferenceYin and Chen, 2013 (definition) and policy evidence summary (see EGG/BSGM evidence assessments).

Gastroparesis

DefinitionA digestive disorder in which stomach motility is abnormal or absent; also known as delayed gastric emptying.

Typical causes and impactDiabetes is a common cause; symptoms include nausea, vomiting, early satiety, bloating, and abdominal pain.

Treatment contextGES may be considered for medically refractory diabetic or idiopathic gastroparesis per society guidance when standard therapies have failed.

Magnetic Resonance Defecography

DefinitionA noninvasive MRI-based test that obtains images at various stages of defecation to evaluate pelvic floor anatomy, dynamic motion, and rectal evacuation simultaneously.

Role in evaluationCan provide anatomic and dynamic detail of pelvic compartments and may include evacuation-phase imaging to increase sensitivity for rectocele and enterocele.

LimitationsMRD may under-detect some abnormalities versus fluoroscopic evacuation proctography and is not considered a replacement for EP as the reference standard without validation.

GES (Gastric Electrical Stimulation)

DefinitionImplantable gastric electrical stimulation (GES) systems (e.g., Enterra) that deliver electrical pulses to the stomach for treatment of medically refractory gastroparesis symptoms.

Regulatory statusEnterra System is a humanitarian device exemption (HDE) per FDA labeling; use should follow FDA labeling and institutional oversight where applicable.

Clinical contextSociety guidance (ACG/AGA) provides conditional recommendations for GES in refractory diabetic or idiopathic gastroparesis after failure of standard therapy.

MRI Defecography (MRD)

DefinitionDynamic MRI imaging technique to evaluate pelvic floor and defecatory function; may include an evacuation phase to increase sensitivity for certain abnormalities.

Clinical useUsed adjunctively when ARM and BET are equivocal or when additional anatomic detail is needed to guide management of obstructed defecation.

Diagnostic cautionTechnical success and sensitivity vary; inconclusive MRD studies may necessitate repeat testing or complementary studies such as EP.

EGG/BSGM

DefinitionSurface recordings of gastric myoelectrical activity (electrogastrography) and advanced noninvasive body surface gastric mapping devices intended to detect gastric rhythm abnormalities.

Evidence summarySystematic reviews and cohort studies report detection of rhythm abnormalities, but evidence is heterogeneous and low quality with insufficient data proving clinical utility or outcome benefit.

Research considerationsStandardized protocols, larger diagnostic accuracy studies, and clinical utility trials are needed before routine clinical adoption.

BSGM (Body Surface Gastric Mapping)

DefinitionA noninvasive, high-resolution surface electrode mapping technique (e.g., Gastric Alimetry) that records spatial and spectral gastric myoelectrical biomarkers and can provide patient-level phenotyping.

Performance signalsRecent studies report higher detection rates of spectral abnormalities and improved symptom correlations and classification accuracy compared with traditional EGG or gastric emptying testing, but clinical utility remains unproven.

Evidence limitationsExisting studies have heterogeneous protocols, small samples, and lack demonstration that BSGM-guided management improves patient outcomes.

MI (Mucosal Impedance) testing

DefinitionMeasurement of esophageal epithelial impedance performed during endoscopy using balloon catheters or contact probes (e.g., MiVu) to assess mucosal integrity patterns associated with GERD, EoE, and non-GERD conditions.

Regulatory noteThe MiVu Mucosal Integrity Testing System received FDA de novo clearance (Class II) in 2019 and a 510(k) in 2023 (K230056; product code QIS).

Evidence stancePublished studies are limited and of low quality; systematic reviews conclude insufficient evidence that MI testing changes management or improves outcomes, and the policy lists electrical-impedance MI testing as unproven and not medically necessary.

Esophageal Mucosal Integrity Testing — defined term

Definition added to policyEsophageal Mucosal Integrity Testing: An adjunct procedure to routine endoscopy intended to help differentiate GERD from non-GERD and EoE as an alternative to prolonged pH monitoring and biopsies.

Policy change and coverage stancePolicy revision explicitly identifies esophageal mucosal integrity testing by electrical impedance (e.g., MiVu) as unproven and not medically necessary for diagnosis or monitoring of GERD and EoE due to insufficient evidence.

Regulatory referenceMiVu system has FDA de novo clearance (2019) and subsequent 510(k) (K230056, 2023) but FDA clearance alone is not a basis for coverage per policy language.